SCHEMBL17525660

SCHEMBL17525660

CC(C)OC(=O)C[C@H](C)N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
TSHR P16473 2/20 0.42
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39
MMP9 P14780 1/20 0.39
MMP13 P45452 1/20 0.39
GABRP O00591 2/20 0.36
GABRD O14764 2/20 0.36
GABRA1 P14867 2/20 0.36
GABRB1 P18505 2/20 0.36
GABRG2 P18507 2/20 0.36
GABRB3 P28472 2/20 0.36
GABRA5 P31644 2/20 0.36
GABRA3 P34903 2/20 0.36
GABRA2 P47869 2/20 0.36
GABRB2 P47870 2/20 0.36
GABRA4 P48169 2/20 0.36
GABRE P78334 2/20 0.36
GABRA6 Q16445 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18502988 1.00 LMNA (0.43) LMNATSHRMMP1MMP2MMP3
SCHEMBL6432055 1.00 LMNA (0.43) LMNATSHRMMP1MMP2MMP3
Hydrochloric Acid SCHEMBL18496191 0.98 LMNA (0.42) LMNATSHRMMP1MMP2MMP3
Hydrochloric Acid SCHEMBL18496190 0.98 LMNA (0.42) LMNATSHRMMP1MMP2MMP3
Hydrochloric Acid SCHEMBL28854944 0.98 LMNA (0.42) LMNATSHRMMP1MMP2MMP3
SCHEMBL18502990 0.81 LMNA (0.41) LMNATSHRMMP1MMP2MMP3
SCHEMBL23418403 0.79 LMNA (0.44) LMNATSHRMMP1MMP2MMP3
SCHEMBL6435735 0.79 LMNA (0.39) LMNATSHRMMP1MMP2MMP3
SCHEMBL6435729 0.79 LMNA (0.39) LMNATSHRMMP1MMP2MMP3
SCHEMBL19387301 0.79 CYP19A1 (0.43) LMNATSHRMMP1MMP2MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250215465-A1 ENANTIOSELECTIVE METHODS FOR PREPARING CHIRAL AMINE INTERMEDIATES UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG (ZA) 2025-07-03 US disclosed
EP-4493708-A1 ENANTIOSELECTIVE METHODS FOR PREPARING CHIRAL AMINE INTERMEDIATES University of the Witwatersrand, Johannesburg (ZA) 2025-01-22 EP disclosed
CN-118974266-A Enantioselective process for preparing chiral amine intermediates 约翰内斯堡威特沃特斯兰德大学 2024-11-15 CN disclosed
EP-3279207-B1 NOVEL COMPOUND OF 4'-THIONUCLEOSIDE, AS WELL AS PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) 2024-01-24 EP disclosed
WO-2023197017-A1 ENANTIOSELECTIVE METHODS FOR PREPARING CHIRAL AMINE INTERMEDIATES UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG (ZA) 2023-10-12 WO disclosed
US-20230295201-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2023-09-21 US disclosed
US-20230295201-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2023-09-21 US disclosed
US-20180065999-A1 ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2018-03-08 US disclosed
US-20180065999-A1 ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2018-03-08 US disclosed
US-9822138-B2 Antiviral beta-amino acid ester phosphodiamide compounds MERCK SHARP & DOHME CORP. (US) 2017-11-21 US disclosed
US-9822138-B2 Antiviral beta-amino acid ester phosphodiamide compounds MERCK SHARP & DOHME CORP. (US) 2017-11-21 US disclosed
US-20170044192-A1 ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2017-02-16 US disclosed
US-20170044192-A1 ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2017-02-16 US disclosed
WO-2017027434-A1 ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2017-02-16 WO disclosed
EP-1539980-B1 LIBRARY OF COMPLEXES COMPRISING SMALL NON-PEPTIDE MOLECULES AND DOUBLE-STRANDED OLIGONUCLEOTIDES IDENTIFYING THE MOLECULES NUEVOLUTION AS (DK) 2016-02-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295201-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 LMNA 3047/4885TSHR 2321/4885MMP1 4465/4885
US-20170044192-A1 ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS POLD1, PEPD, TYMP LMNA 3944/4885TSHR 4790/4885MMP1 3442/4885
US-20180065999-A1 ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS POLD1, PEPD, TYMP LMNA 3944/4885TSHR 4790/4885MMP1 3442/4885
US-20250215465-A1 ENANTIOSELECTIVE METHODS FOR PREPARING CHIRAL AMINE INTERMEDIATES BCAT1, BCAT2, CES1 LMNA 1726/4885TSHR 1369/4885MMP1 2796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.